[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Achieve Life Sciences Inc (ACHV)

Achieve Life Sciences Inc (ACHV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 214,001
  • Shares Outstanding, K 53,234
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,650 K
  • EBIT $ -55 M
  • EBITDA $ -55 M
  • 60-Month Beta 1.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.27

Options Overview Details

View History
  • Implied Volatility 125.35% (+25.42%)
  • Historical Volatility 151.48%
  • IV Percentile 31%
  • IV Rank 7.38%
  • IV High 656.67% on 03/02/26
  • IV Low 82.99% on 07/02/25
  • Expected Move (DTE 20) 0.17 (4.23%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 304
  • Volume Avg (30-Day) 899
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 32,391
  • Open Int (30-Day) 29,675
  • Expected Range 3.85 to 4.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 1
  • High Estimate $-0.30
  • Low Estimate $-0.30
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) +18.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.62 +53.44%
on 03/30/26
5.30 -24.15%
on 04/20/26
+1.12 (+38.62%)
since 03/24/26
3-Month
2.62 +53.44%
on 03/30/26
5.53 -27.33%
on 01/26/26
-1.58 (-28.21%)
since 01/23/26
52-Week
2.00 +101.00%
on 06/27/25
6.03 -33.28%
on 01/16/26
+1.62 (+67.50%)
since 04/24/25

Most Recent Stories

More News
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors  New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences Announces Up to $354 Million Private Placement

$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations,...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

SEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Achieve also Announces Partnership with U.S.-based   Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER,...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...

ACHV : 4.02 (-3.13%)
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

SEATTLE and VANCOUVER, BC , Dec. 17, 2025 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization...

ACHV : 4.02 (-3.13%)

Business Summary

Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc.,...

See More

Key Turning Points

3rd Resistance Point 4.42
2nd Resistance Point 4.30
1st Resistance Point 4.16
Last Price 4.02
1st Support Level 3.91
2nd Support Level 3.79
3rd Support Level 3.65

See More

52-Week High 6.03
Fibonacci 61.8% 4.49
Last Price 4.02
Fibonacci 50% 4.01
Fibonacci 38.2% 3.54
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.